• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home Weekly Rewinds

2 Minute Medicine Rewind October 3, 2016

byNavid AhmedandDavid Ouyang
October 12, 2016
in Weekly Rewinds
Reading Time: 5 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Changes in moderate-to-vigorous physical activity among older adolescents

While the Centers for Disease Control and Prevention recommend at least 60 minutes of moderate to vigorous physical activity (MVPA) for adolescents daily, data suggests that this goal is not being met. The purpose of this study was to examine determinants of objectively measured MVPA (assessed using accelerometers) over 4 years in young adults in the US. The authors used a combination of accelerometers, self reported physical activity, BMI, and other variables among a longitudinal cohort (n = 561) of adolescents to examine activity levels. The researchers found that less than 9% of participants met the recommended 60+ minutes/day MVPA. MVPA was also greater in males vs females (p < 0.001), Hispanics vs White (p < 0.001), and increased BMI was associated with decreased MVPA. In young adults, attending a 4-year college and living on campus were associated with higher levels of MVPA when compared to those not attending school or living off campus. The authors concluded that high-school students in general, engaged in little MVPA and maintained this low level through the transition into adulthood and that social context may play a large role in activity levels and may serve as a target for intervention.

Effectiveness of fluticasone furoate–vilanterol for COPD in clinical practice

The evidence of chronic obstructive pulmonary disease (COPD) was established from randomized control trials with strict criteria and raised questions as to whether the results from these trials would be generalizable to clinical practice. In a controlled effectiveness trial, 2799 patients with COPD were randomly assigned to once daily inhaled combination of fluticasone furoate and vilanterol (fluticasone furoate – vilanterol group) or to usual care. The primary outcome of interest was the rate of moderate to severe exacerbation within 1 year before the trial and secondary outcomes were analyzed based only on the entire trial population and included the rate of first exacerbation, annual rates of primary care contact, and the rate of serious adverse events. The rate of moderate or severe exacerbation was significantly lower by 8.4% with fluticasone furoate – vilanterol group compared to usual care (95% CI: 1.1 to 15.2, p = 0.02). There was no significant difference between the annual rate of COPD related contact with primary care between groups or in the rate of first exacerbation in the time to event analysis between treatment groups. The incidence of adverse events was similar in both groups however a trend towards an increased number of cases of pneumonia in the group in the treatment arm without an inhaled glucocorticoid was noted. The authors concluded that in patients with COPD and a history of exacerbations, once daily treatment regimen of combined fluticasone furoate – vilanterol was associated with a lower rate of exacerbations than usual care without a greater risk of adverse events.

“Housing First” for homeless youth with mental illness

Although “Housing First” has been showed to be effective in improving housing stability in homeless individuals with mental illness, its effectiveness has not been tested in homeless youth.  The purpose of this report was to test the effect of “Housing First” on housing stability in 156 homeless youth aged 18-24 in a 24 month randomized trial of “Housing First” in 5 Canadian cities.  87 of these subjects received “Housing First” and 69 received treatment as usual. The majority of data was collected by in-person interviews and the primary outcome of the study was housing stability. In an adjusted analysis, youth in “Housing First” were stably housed a mean of 437 out of 645 (65%) days compared to youth in treatment as usual group who were stably housed a mean of 189 out of 582 (31%) resulting in an adjusted mean difference of 34% (95% CI: 24% to 45%; p< 0.001). The authors concluded that “Housing First” was associated with improved housing stability in homeless youth with mental illness.

RELATED REPORTS

In selected patients with anterior-circulation large-vessel stroke 24-72 hours after onset, thrombectomy improved 90-day function but increased hemorrhage and death

Cannabis use, including smoked or edible, linked to higher stroke risk

Association of nausea and vomiting during pregnancy with pregnancy loss

Although nausea and vomiting are common symptoms of clinical pregnancy, a prior study suggested that the absence of these signs may be a possible marker of pregnancy loss.  The purpose of this study was to examine the association of nausea and vomiting during pregnancy with pregnancy loss. This study was an ad hoc secondary analysis of patients recruited in a multi-center randomized placebo-controlled trial of aspirin use to prevent pregnancy loss (Effects of Aspirin in Gestation and Reproduction study). A total of 797 women have bHCG confirmed pregnancy and 188 of these pregnancies (23.6%) ended in a loss. At gestational week 2, 73 out of 309 women reported nausea without vomiting and 11 out of 409 reported nausea with vomiting. By week 8, the proportions increased to 254 of 443 and 118 of 443 respectively.  Furthermore, women with nausea had a hazard ratio of 0.50 (95% CI: 0.32 to 0.82) for pregnancy loss, while those with vomiting had a HR of 0.25 (95% CI: 0.12 to 0.51). Among those with clinical pregnancy, nausea had a HR of 0.44 (95% CI: 0.26 to 0.74) and vomiting had a HR of 0.20 (95% CI: 0.09 to 0.44) The study concluded that among women with 1 or 2 prior pregnancy losses, nausea and vomiting were common early in pregnancy and associated with a reduced risk of loss and there was an inverse relationship between symptoms of nausea and vomiting with pregnancy loss.

Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke

Although the clinical benefit of endovascular thrombectomy has been established for patients with an ischemic stroke, the relative benefit compared to medical therapies and timing of intervention remains uncertain. The purpose of this study was to characterize the period in which endovascular thrombectomy is associated with benefit and the extent to which treatment delay is related to mortality, functional outcomes, and symptomatic intracranial hemorrhage. This was a pooled meta-analysis that reviewed findings from 5 randomized control trials comparing patients who received either endovascular thrombectomy and medical therapy, or medical therapy alone. The primary outcome was degree of disability at 3 months and secondary endpoints included mortality at 3 months and functional independence. A total of 1287 patients were included and 634 received endovascular thrombectomy along with medical therapy and 653 patients received medical therapy alone. 1287 patients were included in the study where 634 patients of the total received endovascular thrombectomy along with medical therapy and 653 patients received medical therapy alone. Endovascular thrombectomy was associated with a significantly lower degree of disability at 3 months compared to medical therapy alone (mRS = 2.9, 95% CI: 2.7 to 3.1; vs. 3.6, 95% CI: 3.5 to 3.8 respectively). Furthermore, the authors reported that the degree of benefit from endovascular thrombectomy declined in a step-wise fashion with longer durations from symptom onset to arterial puncture (3 hours: cOR 2.79, 95%CI: 1.96 to 3.98; 6 hours: cOR 1.98, 95% CI: 1.30 to 3.00; 8 hours: cOR 1.57, 95% CI: 0.86to 2.88). As a result, the authors concluded that in patients with large vessel ischemic stroke, earlier treatment with endovascular thrombectomy and medical therapy compared with medical therapy alone was associated with lower degrees of disability at 3 months.

FDA approvedFor stroke: Sunharbo (asundexian), Nov 9, 2026→

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: copdstroke
Previous Post

Rivaroxaban associated with increased bleeding risk compared with dabigatran in nonvalvular atrial fibrillation

Next Post

Therapeutic hypothermia shows no benefit for in-hospital cardiac arrest

RelatedReports

Stroke treatment collage: an engraved brain with teal arteries and one blocked branch, a coiled catheter and a stopwatch
Emergency

In selected patients with anterior-circulation large-vessel stroke 24-72 hours after onset, thrombectomy improved 90-day function but increased hemorrhage and death

November 7, 2026
Cannabis and mental health collage: a thoughtful young man with curly hair, a flat cannabis leaf and three blank shopfronts
Cardiology

Cannabis use, including smoked or edible, linked to higher stroke risk

November 6, 2026
AI-read breathing tests collage: an older woman in a cardigan, a teal breathing loop on graph paper and a mouthpiece tube
Artificial Intelligence

Artificial intelligence decision support software improved spirometry diagnosis performance in primary care

May 12, 2026
Atrial fibrillation collage: an engraved heart with teal upper chambers, paper sparks and a dotted teal ribbon around it
Weekly Rewinds

2 Minute Medicine Rewind November 3rd, 2025

January 13, 2026
Next Post

Therapeutic hypothermia shows no benefit for in-hospital cardiac arrest

Higher risk of type 2 diabetes associated with LDL-C-lowering genetic variants

Adding daratumumab increases progression free survival in multiple myeloma

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medicaid-reimbursed weight-loss GLP-1 prescriptions fell after coverage withdrawal in 4 states
  • Social isolation and loneliness is associated with worse physical and mental health among middle-aged and older adults
  • Gait analysis predicts health, sleep, and medication use across 18 body systems
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.